Abstract
In this week's Neurology , Draak et al.1 report the results of their comparison between the patient-reported Inflammatory Rasch-built Overall Disability Scale (I-RODS) and the clinician-reported Inflammatory Neuropathy Cause and Treatment–Overall Neuropathy Limitation Scale (INCAT-ONLS) in patients with immune-mediated neuropathies, including Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The arithmetic difficulty of Rasch methodology (see below for a description) and lack of familiarity with the field of clinimetrics (the science of measurement in a clinical setting) make this article a challenging read and risk obscuring its important messages for clinical trial design, including the utility of patient-reported outcome measures (PROMs), the power of Rasch analysis, and a focus on minimal clinically important difference (MCID) as a means of assessing treatment response.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
